Pamela Pierce Palmer
Net Worth
Last updated:
What is Pamela Pierce Palmer net worth?
The estimated net worth of Dr. Pamela Pierce Palmer is at least $9,479,876 as of 25 Aug 2023. He has earned $19,236 from insider trading and has received compensation worth at least $9,460,640 in AcelRx Pharmaceuticals, Inc..
What is the salary of Pamela Pierce Palmer?
Dr. Pamela Pierce Palmer salary is $675,760 per year as Co-Founder, Chief Medical Officer & Director in AcelRx Pharmaceuticals, Inc..
How old is Pamela Pierce Palmer?
Dr. Pamela Pierce Palmer is 62 years old, born in 1963.
What stocks does Pamela Pierce Palmer currently own?
As insider, Dr. Pamela Pierce Palmer owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| AcelRx Pharmaceuticals, Inc. (ACRX) | Co-Founder, Chief Medical Officer & Director | 30,753 | $0 | $0 |
What does AcelRx Pharmaceuticals, Inc. do?
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Pamela Pierce Palmer insider trading
AcelRx Pharmaceuticals, Inc.
Dr. Pamela Pierce Palmer has made 2 insider trades between 2011-2023, according to the Form 4 filled with the SEC. Most recently he sold 7,442 units of ACRX stock worth $8,104 on 25 Aug 2023.
The largest trade he's ever made was exercising 37,000 units of ACRX stock on 6 Aug 2018. As of 25 Aug 2023 he still owns at least 30,753 units of ACRX stock.
AcelRx Pharmaceuticals key executives
AcelRx Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Pamela Pierce Palmer (62) Co-Founder, Chief Medical Officer & Director
- Mr. Anil N. Dasu (62) Chief Engineering Officer
- Mr. Raffi Mark Asadorian (56) Chief Financial Officer
- Mr. Vincent J. Angotti (57) Chief Executive Officer & Director